I am Elena Olmastroni, a post doc researcher at the Department of Pharmacological and Biomolecular Sciences of the University of Milan (Italy). I completed a master degree in Biostatistics at the University of Milan-Bicocca (Italy) in 2017, with a thesis on “Nested case-control studies to assess the association between pioglitazone use and bladder cancer risk in a Swedish cohort with type 2 diabetes”, a project conducted in collaboration with the Centre for Pharmacoepidemiology of the Karolinska Institutet (Sweden). Then, I got a PhD in Experimental, Clinical and Biomolecular Pharmacological Science in April 2022. During my PhD programme, I have gain experiences and improved skills related to: •integrate and use the pharmacological knowledge acquired in order to developing interdisciplinary pharmacoepidemiological studies in the field of health science; •design, conduction and analysis of pharmacoepidemiology and pharmacoutilization studies, mainly through healthcare utilization databases; •the evaluation of the risk/benefit profile of drugs in the context of real-world clinical practice, through both the use of administrative databases and the application of meta-analytic methodologies based on the published results of clinical and/or experimental studies.


Combining family history of coronary heart disease and individual genetic predisposition to accurately predict the lifetime risk of major coronary events91th EAS Congress 2023Genetics of dyslipidemiasLipoprotein(A) does not have a clinically significant arterial or venous prothrombotic effectLate breaker session 290th EAS Congress 2022